Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent ...

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...

Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back ...

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...